Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults
Dengue virus (DENV) and Japanese encephalitis virus (JEV) belong to the genus Flavivirus, and infection with a virus within this genus induces antibodies that are cross-reactive to other flaviviruses. Particularly in DENV infection, antibodies to DENV possess two competing activities: neutralizing a...
Gespeichert in:
| Veröffentlicht in: | BMC infectious diseases 2016-10, Vol.16 (1), p.578-578, Article 578 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 578 |
|---|---|
| container_issue | 1 |
| container_start_page | 578 |
| container_title | BMC infectious diseases |
| container_volume | 16 |
| creator | Saito, Yuka Moi, Meng Ling Takeshita, Nozomi Lim, Chang-Kweng Shiba, Hajime Hosono, Kuniaki Saijo, Masayuki Kurane, Ichiro Takasaki, Tomohiko |
| description | Dengue virus (DENV) and Japanese encephalitis virus (JEV) belong to the genus Flavivirus, and infection with a virus within this genus induces antibodies that are cross-reactive to other flaviviruses. Particularly in DENV infection, antibodies to DENV possess two competing activities: neutralizing activity and infection-enhancing activity. These antibody activities are considered central in modulating clinical outcomes of DENV infection. Here, we determined the neutralizing and infection-enhancing activity of DENV cross-reactive antibodies in adults before and after JE vaccination.
Participants were 77 Japanese adults who had received a single dose of inactivated Vero cell-derived JE vaccine. A total of 154 serum samples were obtained either before or approximately a month after a single dose of JE vaccination. The antibody-dependent enhancement (ADE) activity to each of four DENV serotypes and the neutralizing activities to DENV and to JEV were determined in each of the serum samples by using baby hamster kidney (BHK) cells and FcγR-expressing BHK cells.
A total of 18 post-JE immunization samples demonstrated cross-reactivity to DENV in an anti-DENV IgG ELISA. DENV neutralizing antibodies were not detected after JE vaccination in this study. However, undiluted post-JE vaccination serum samples from 26 participants demonstrated monotypic and heterotypic ADE activity to DENV. ADE activity was also observed in 1:10-diluted samples from 35 of the JE vaccine recipients (35/77, 45 %).
In summary, JE vaccination induced DENV cross-reactive antibodies, and at sub-neutralizing levels, these DENV cross-reactive antibodies possess DENV infection-enhancement activity. The results also indicate that cross-reactivity to DENV is associated with high levels of JEV neutralizing antibodies and, the DENV cross-reactivity is further facilitated by JE vaccination. |
| doi_str_mv | 10.1186/s12879-016-1873-8 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5070094</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A470590072</galeid><sourcerecordid>A470590072</sourcerecordid><originalsourceid>FETCH-LOGICAL-c606t-cfdf1bc615d0b0f1e02a3c6ce493136d5da4395dd937d77d1fbdefe30734f3d23</originalsourceid><addsrcrecordid>eNqNkk1v1DAQhi0EoqXwA7igSFzgkNYTJ3ZyQaqqAkWVKvF1tRx7vOsqsZfYWdF_X0dbShdxqHywNfO845lXQ8hroMcALT-JULWiKynwElrByvYJOYRaQFkxVj998D4gL2K8phREW3XPyUElRMMrqA6J_KI2ymPEAr3GzVoNLrlYbJXWzmNplXY5ohKawqBfzVhs3TTHwnmLOrngS_RrlaUj-lQon1wfzE1OF8rMQ4ovyTOrhoiv7u4j8uPj-fezz-Xl1aeLs9PLUnPKU6mtsdBrDo2hPbWAtFJMc411x4Bx0xhVs64xpmPCCGHA9gYtMipYbZmp2BH5sKu7mfsRjc7dTGqQm8mNarqRQTm5n_FuLVdhKxsqKO3qXODdXYEp_JoxJjm6qHEYsjthjhJa1tTdYntG3_6DXod58nm8hcodc2jhL7VSA8rsV8j_6qWoPK0FbTpKxdL38X-ofAyOTgeP1uX4nuD9niAzCX-nlZpjlBffvj6evfq5z8KO1VOIcUJ77x1QuYwtd9sm87bJZdtkmzVvHpp-r_izXuwWrbPPbg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1834936181</pqid></control><display><type>article</type><title>Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><source>Springer Nature - Complete Springer Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Saito, Yuka ; Moi, Meng Ling ; Takeshita, Nozomi ; Lim, Chang-Kweng ; Shiba, Hajime ; Hosono, Kuniaki ; Saijo, Masayuki ; Kurane, Ichiro ; Takasaki, Tomohiko</creator><creatorcontrib>Saito, Yuka ; Moi, Meng Ling ; Takeshita, Nozomi ; Lim, Chang-Kweng ; Shiba, Hajime ; Hosono, Kuniaki ; Saijo, Masayuki ; Kurane, Ichiro ; Takasaki, Tomohiko</creatorcontrib><description>Dengue virus (DENV) and Japanese encephalitis virus (JEV) belong to the genus Flavivirus, and infection with a virus within this genus induces antibodies that are cross-reactive to other flaviviruses. Particularly in DENV infection, antibodies to DENV possess two competing activities: neutralizing activity and infection-enhancing activity. These antibody activities are considered central in modulating clinical outcomes of DENV infection. Here, we determined the neutralizing and infection-enhancing activity of DENV cross-reactive antibodies in adults before and after JE vaccination.
Participants were 77 Japanese adults who had received a single dose of inactivated Vero cell-derived JE vaccine. A total of 154 serum samples were obtained either before or approximately a month after a single dose of JE vaccination. The antibody-dependent enhancement (ADE) activity to each of four DENV serotypes and the neutralizing activities to DENV and to JEV were determined in each of the serum samples by using baby hamster kidney (BHK) cells and FcγR-expressing BHK cells.
A total of 18 post-JE immunization samples demonstrated cross-reactivity to DENV in an anti-DENV IgG ELISA. DENV neutralizing antibodies were not detected after JE vaccination in this study. However, undiluted post-JE vaccination serum samples from 26 participants demonstrated monotypic and heterotypic ADE activity to DENV. ADE activity was also observed in 1:10-diluted samples from 35 of the JE vaccine recipients (35/77, 45 %).
In summary, JE vaccination induced DENV cross-reactive antibodies, and at sub-neutralizing levels, these DENV cross-reactive antibodies possess DENV infection-enhancement activity. The results also indicate that cross-reactivity to DENV is associated with high levels of JEV neutralizing antibodies and, the DENV cross-reactivity is further facilitated by JE vaccination.</description><identifier>ISSN: 1471-2334</identifier><identifier>EISSN: 1471-2334</identifier><identifier>DOI: 10.1186/s12879-016-1873-8</identifier><identifier>PMID: 27756212</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adult ; Analysis ; Animals ; Antibodies ; Antibodies, Neutralizing - blood ; Antibodies, Viral - blood ; Antibody-Dependent Enhancement ; Care and treatment ; Cercopithecus aethiops ; Complications and side effects ; Cricetinae ; Cross Reactions ; Dengue - immunology ; Dengue - virology ; Dengue Virus - immunology ; Dengue Virus - pathogenicity ; Dengue viruses ; Encephalitis Virus, Japanese - immunology ; Encephalitis, Japanese - immunology ; Encephalitis, Japanese - virology ; Female ; Health aspects ; Humans ; Infectious diseases ; Japanese encephalitis ; Japanese Encephalitis Vaccines - adverse effects ; Japanese Encephalitis Vaccines - immunology ; Male ; Middle Aged ; Risk factors ; Vaccination ; Vaccines, Inactivated - immunology ; Vero Cells ; Viral antibodies</subject><ispartof>BMC infectious diseases, 2016-10, Vol.16 (1), p.578-578, Article 578</ispartof><rights>COPYRIGHT 2016 BioMed Central Ltd.</rights><rights>Copyright BioMed Central 2016</rights><rights>The Author(s). 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c606t-cfdf1bc615d0b0f1e02a3c6ce493136d5da4395dd937d77d1fbdefe30734f3d23</citedby><cites>FETCH-LOGICAL-c606t-cfdf1bc615d0b0f1e02a3c6ce493136d5da4395dd937d77d1fbdefe30734f3d23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070094/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070094/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27756212$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Saito, Yuka</creatorcontrib><creatorcontrib>Moi, Meng Ling</creatorcontrib><creatorcontrib>Takeshita, Nozomi</creatorcontrib><creatorcontrib>Lim, Chang-Kweng</creatorcontrib><creatorcontrib>Shiba, Hajime</creatorcontrib><creatorcontrib>Hosono, Kuniaki</creatorcontrib><creatorcontrib>Saijo, Masayuki</creatorcontrib><creatorcontrib>Kurane, Ichiro</creatorcontrib><creatorcontrib>Takasaki, Tomohiko</creatorcontrib><title>Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults</title><title>BMC infectious diseases</title><addtitle>BMC Infect Dis</addtitle><description>Dengue virus (DENV) and Japanese encephalitis virus (JEV) belong to the genus Flavivirus, and infection with a virus within this genus induces antibodies that are cross-reactive to other flaviviruses. Particularly in DENV infection, antibodies to DENV possess two competing activities: neutralizing activity and infection-enhancing activity. These antibody activities are considered central in modulating clinical outcomes of DENV infection. Here, we determined the neutralizing and infection-enhancing activity of DENV cross-reactive antibodies in adults before and after JE vaccination.
Participants were 77 Japanese adults who had received a single dose of inactivated Vero cell-derived JE vaccine. A total of 154 serum samples were obtained either before or approximately a month after a single dose of JE vaccination. The antibody-dependent enhancement (ADE) activity to each of four DENV serotypes and the neutralizing activities to DENV and to JEV were determined in each of the serum samples by using baby hamster kidney (BHK) cells and FcγR-expressing BHK cells.
A total of 18 post-JE immunization samples demonstrated cross-reactivity to DENV in an anti-DENV IgG ELISA. DENV neutralizing antibodies were not detected after JE vaccination in this study. However, undiluted post-JE vaccination serum samples from 26 participants demonstrated monotypic and heterotypic ADE activity to DENV. ADE activity was also observed in 1:10-diluted samples from 35 of the JE vaccine recipients (35/77, 45 %).
In summary, JE vaccination induced DENV cross-reactive antibodies, and at sub-neutralizing levels, these DENV cross-reactive antibodies possess DENV infection-enhancement activity. The results also indicate that cross-reactivity to DENV is associated with high levels of JEV neutralizing antibodies and, the DENV cross-reactivity is further facilitated by JE vaccination.</description><subject>Adult</subject><subject>Analysis</subject><subject>Animals</subject><subject>Antibodies</subject><subject>Antibodies, Neutralizing - blood</subject><subject>Antibodies, Viral - blood</subject><subject>Antibody-Dependent Enhancement</subject><subject>Care and treatment</subject><subject>Cercopithecus aethiops</subject><subject>Complications and side effects</subject><subject>Cricetinae</subject><subject>Cross Reactions</subject><subject>Dengue - immunology</subject><subject>Dengue - virology</subject><subject>Dengue Virus - immunology</subject><subject>Dengue Virus - pathogenicity</subject><subject>Dengue viruses</subject><subject>Encephalitis Virus, Japanese - immunology</subject><subject>Encephalitis, Japanese - immunology</subject><subject>Encephalitis, Japanese - virology</subject><subject>Female</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Japanese encephalitis</subject><subject>Japanese Encephalitis Vaccines - adverse effects</subject><subject>Japanese Encephalitis Vaccines - immunology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Risk factors</subject><subject>Vaccination</subject><subject>Vaccines, Inactivated - immunology</subject><subject>Vero Cells</subject><subject>Viral antibodies</subject><issn>1471-2334</issn><issn>1471-2334</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNqNkk1v1DAQhi0EoqXwA7igSFzgkNYTJ3ZyQaqqAkWVKvF1tRx7vOsqsZfYWdF_X0dbShdxqHywNfO845lXQ8hroMcALT-JULWiKynwElrByvYJOYRaQFkxVj998D4gL2K8phREW3XPyUElRMMrqA6J_KI2ymPEAr3GzVoNLrlYbJXWzmNplXY5ohKawqBfzVhs3TTHwnmLOrngS_RrlaUj-lQon1wfzE1OF8rMQ4ovyTOrhoiv7u4j8uPj-fezz-Xl1aeLs9PLUnPKU6mtsdBrDo2hPbWAtFJMc411x4Bx0xhVs64xpmPCCGHA9gYtMipYbZmp2BH5sKu7mfsRjc7dTGqQm8mNarqRQTm5n_FuLVdhKxsqKO3qXODdXYEp_JoxJjm6qHEYsjthjhJa1tTdYntG3_6DXod58nm8hcodc2jhL7VSA8rsV8j_6qWoPK0FbTpKxdL38X-ofAyOTgeP1uX4nuD9niAzCX-nlZpjlBffvj6evfq5z8KO1VOIcUJ77x1QuYwtd9sm87bJZdtkmzVvHpp-r_izXuwWrbPPbg</recordid><startdate>20161018</startdate><enddate>20161018</enddate><creator>Saito, Yuka</creator><creator>Moi, Meng Ling</creator><creator>Takeshita, Nozomi</creator><creator>Lim, Chang-Kweng</creator><creator>Shiba, Hajime</creator><creator>Hosono, Kuniaki</creator><creator>Saijo, Masayuki</creator><creator>Kurane, Ichiro</creator><creator>Takasaki, Tomohiko</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QL</scope><scope>7T2</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20161018</creationdate><title>Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults</title><author>Saito, Yuka ; Moi, Meng Ling ; Takeshita, Nozomi ; Lim, Chang-Kweng ; Shiba, Hajime ; Hosono, Kuniaki ; Saijo, Masayuki ; Kurane, Ichiro ; Takasaki, Tomohiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c606t-cfdf1bc615d0b0f1e02a3c6ce493136d5da4395dd937d77d1fbdefe30734f3d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Analysis</topic><topic>Animals</topic><topic>Antibodies</topic><topic>Antibodies, Neutralizing - blood</topic><topic>Antibodies, Viral - blood</topic><topic>Antibody-Dependent Enhancement</topic><topic>Care and treatment</topic><topic>Cercopithecus aethiops</topic><topic>Complications and side effects</topic><topic>Cricetinae</topic><topic>Cross Reactions</topic><topic>Dengue - immunology</topic><topic>Dengue - virology</topic><topic>Dengue Virus - immunology</topic><topic>Dengue Virus - pathogenicity</topic><topic>Dengue viruses</topic><topic>Encephalitis Virus, Japanese - immunology</topic><topic>Encephalitis, Japanese - immunology</topic><topic>Encephalitis, Japanese - virology</topic><topic>Female</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Japanese encephalitis</topic><topic>Japanese Encephalitis Vaccines - adverse effects</topic><topic>Japanese Encephalitis Vaccines - immunology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Risk factors</topic><topic>Vaccination</topic><topic>Vaccines, Inactivated - immunology</topic><topic>Vero Cells</topic><topic>Viral antibodies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Saito, Yuka</creatorcontrib><creatorcontrib>Moi, Meng Ling</creatorcontrib><creatorcontrib>Takeshita, Nozomi</creatorcontrib><creatorcontrib>Lim, Chang-Kweng</creatorcontrib><creatorcontrib>Shiba, Hajime</creatorcontrib><creatorcontrib>Hosono, Kuniaki</creatorcontrib><creatorcontrib>Saijo, Masayuki</creatorcontrib><creatorcontrib>Kurane, Ichiro</creatorcontrib><creatorcontrib>Takasaki, Tomohiko</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMC infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saito, Yuka</au><au>Moi, Meng Ling</au><au>Takeshita, Nozomi</au><au>Lim, Chang-Kweng</au><au>Shiba, Hajime</au><au>Hosono, Kuniaki</au><au>Saijo, Masayuki</au><au>Kurane, Ichiro</au><au>Takasaki, Tomohiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults</atitle><jtitle>BMC infectious diseases</jtitle><addtitle>BMC Infect Dis</addtitle><date>2016-10-18</date><risdate>2016</risdate><volume>16</volume><issue>1</issue><spage>578</spage><epage>578</epage><pages>578-578</pages><artnum>578</artnum><issn>1471-2334</issn><eissn>1471-2334</eissn><abstract>Dengue virus (DENV) and Japanese encephalitis virus (JEV) belong to the genus Flavivirus, and infection with a virus within this genus induces antibodies that are cross-reactive to other flaviviruses. Particularly in DENV infection, antibodies to DENV possess two competing activities: neutralizing activity and infection-enhancing activity. These antibody activities are considered central in modulating clinical outcomes of DENV infection. Here, we determined the neutralizing and infection-enhancing activity of DENV cross-reactive antibodies in adults before and after JE vaccination.
Participants were 77 Japanese adults who had received a single dose of inactivated Vero cell-derived JE vaccine. A total of 154 serum samples were obtained either before or approximately a month after a single dose of JE vaccination. The antibody-dependent enhancement (ADE) activity to each of four DENV serotypes and the neutralizing activities to DENV and to JEV were determined in each of the serum samples by using baby hamster kidney (BHK) cells and FcγR-expressing BHK cells.
A total of 18 post-JE immunization samples demonstrated cross-reactivity to DENV in an anti-DENV IgG ELISA. DENV neutralizing antibodies were not detected after JE vaccination in this study. However, undiluted post-JE vaccination serum samples from 26 participants demonstrated monotypic and heterotypic ADE activity to DENV. ADE activity was also observed in 1:10-diluted samples from 35 of the JE vaccine recipients (35/77, 45 %).
In summary, JE vaccination induced DENV cross-reactive antibodies, and at sub-neutralizing levels, these DENV cross-reactive antibodies possess DENV infection-enhancement activity. The results also indicate that cross-reactivity to DENV is associated with high levels of JEV neutralizing antibodies and, the DENV cross-reactivity is further facilitated by JE vaccination.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>27756212</pmid><doi>10.1186/s12879-016-1873-8</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1471-2334 |
| ispartof | BMC infectious diseases, 2016-10, Vol.16 (1), p.578-578, Article 578 |
| issn | 1471-2334 1471-2334 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5070094 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; PubMed Central Open Access; Springer Nature OA Free Journals; Springer Nature - Complete Springer Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adult Analysis Animals Antibodies Antibodies, Neutralizing - blood Antibodies, Viral - blood Antibody-Dependent Enhancement Care and treatment Cercopithecus aethiops Complications and side effects Cricetinae Cross Reactions Dengue - immunology Dengue - virology Dengue Virus - immunology Dengue Virus - pathogenicity Dengue viruses Encephalitis Virus, Japanese - immunology Encephalitis, Japanese - immunology Encephalitis, Japanese - virology Female Health aspects Humans Infectious diseases Japanese encephalitis Japanese Encephalitis Vaccines - adverse effects Japanese Encephalitis Vaccines - immunology Male Middle Aged Risk factors Vaccination Vaccines, Inactivated - immunology Vero Cells Viral antibodies |
| title | Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T19%3A55%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Japanese%20encephalitis%20vaccine-facilitated%20dengue%20virus%20infection-enhancement%20antibody%20in%20adults&rft.jtitle=BMC%20infectious%20diseases&rft.au=Saito,%20Yuka&rft.date=2016-10-18&rft.volume=16&rft.issue=1&rft.spage=578&rft.epage=578&rft.pages=578-578&rft.artnum=578&rft.issn=1471-2334&rft.eissn=1471-2334&rft_id=info:doi/10.1186/s12879-016-1873-8&rft_dat=%3Cgale_pubme%3EA470590072%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1834936181&rft_id=info:pmid/27756212&rft_galeid=A470590072&rfr_iscdi=true |